Muscarinic acetylcholine receptor antagonists

A compound of formula (I)

• wherein:
• R1 is selected from the group consisting of —C1-15 alkyl, halosubstituted —C1-15 alkyl, —C1-15alkyl cycloalkyl, —C2-15 alkenyl, hydroxyl substituted —C1-15 alkyl, —C1-15 alkylaryl, —C1-15 alkyl heteroaryl, —(CR7R7)qNRaRa, —(CR7R7)qNC(O)Ra, —(CR7R7)qNC(O)NRaRa, —(CR7R7)qC(O)Ra, —(CR7R7)qOC(O)Ra, —(CR7R7)qORc, and —(CR7R7)qNS(O)2Ra;
• R2 and R3 are independently selected from the group consisting of:
• wherein F, G, H, K, and L are independently selected from the group consisting of hydrogen, halogen, —C1-4 alkyl, halosubstituted —C1-4 alkyl, hydroxyl substituted alkyl, and —C1-4 alkoxy;
• R7 is selected from a group consisting of hydrogen, —C1-4 alkyl, halosubstituted —C1-4 alkyl, and hydroxysubstituted —C1-4 alkyl;
• Ra is selected from the group consisting of hydrogen, —C1-15 alkyl, —C1-15 alkoxy, aryl, —C1-15 alkyl aryl, heteroaryl, —C1-15 alkyl heteroaryl, heterocyclic, and a —C1-15 alkyl heterocyclic moiety, all of which moieties excluding hydrogen may be optionally substituted;
• Rc is selected from a group consisting of hydrogen, —C1-15 alkyl, —C1-15 alkoxy, heterocyclic, and a —C1-15 alkyl heterocyclic moiety, all of which moieties, excluding hydrogen may be optionally substituted;
• q is 0 or an integer having a value of 1 to 15;
• X− is a pharmaceutically acceptable anion selected from the group consisting of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate, and p-toluenesulfonate.